MedTrace Logo

Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.

NCT04231565 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-03-01

No results posted yet for this study

Summary

This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.

Conditions

  • Hepatitis B Virus

Interventions

DRUG

Tenofovir alafenamide Fumarate

Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.

Sponsors & Collaborators

  • Third Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Liang Peng, Doctor · Third Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-04
Primary Completion
2024-06-01
Completion
2027-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04231565 on ClinicalTrials.gov